Loading…
5 companies · GEL, thousands · columns ordered by revenue
| Company | Sector | EBITDA margin · FY 2024 | Percentile | Sector n |
|---|---|---|---|---|
| Krol Medical Corporation | Healthcare Services | 24.7% | 84th pct | 268 |
| MD Group | Healthcare Services | 21.5% | 79th pct | 268 |
| MedX | Healthcare Services | 14.2% | 63rd pct | 268 |
| K. Tbilisis N3 Samkurna… | Healthcare Services | 3.0% | 29th pct | 268 |
| Family Medicine Regiona… | Healthcare Services | — | no FY data | 268 |
Percentile is within each company's own sector across the whole FY2024 cross-section (1st–100th; higher = larger value). Companies with no sector, or no filing for the year, are not ranked.
| Ratio — FY 2024 | K. Tbilisis N3 Samkurna… | Krol Medical Corporation | MD Group | MedX | Family Medicine Regiona… |
|---|---|---|---|---|---|
| Margins | |||||
| Gross Margin | 95.3% | 100.0% | 83.0% | 92.2% | — |
| EBITDA Margin | 3.0% | 24.7% | 21.5% | 14.2% | — |
| EBITDAR | 19 | 142 | 133 | 74 | — |
| EBITDAR Margin | 3.0% | 24.7% | 25.9% | 14.9% | — |
| EBIT Margin | 2.8% | -47.5% | 1.1% | 2.6% | — |
| Net Profit Margin | 2.8% | -47.5% | -1.8% | -10.8% | — |
| Operating Expense % of Sales | 92.3% | 75.3% | 61.5% | 78.0% | — |
| Returns | |||||
| Return on Assets (ROA) | 0.8% | -17.0% | -0.8% | -5.1% | — |
| Return on Equity (ROE) | 0.9% | -23.3% | -1.8% | -17.9% | — |
| ROIC [EBIT / Invested Capital] | |||||
1 financial-sector filer in this set (Family Medicine Regiona…) report no EBITDA / EBIT / gross profit — banks and insurers structurally don't. Those metrics are blank for them and any pooled EBITDA figure understates this set.
Peers use different ratio blocks (bank / insurer / generic) — a ratio only one template defines is blank for the others.
| 0.9% |
| -23.4% |
| 0.5% |
| 1.3% |
| — |
| Leverage & debt balances | |||||
| Debt-to-Assets | 0.0% | 0.0% | 50.4% | 71.6% | — |
| Debt-to-Equity | 0.00x | 0.00x | 1.18x | 2.52x | — |
| Debt-to-EBITDA | 0.00x | 0.00x | 5.44x | 10.74x | — |
| Equity-to-Assets | 90.0% | 72.9% | 42.8% | 28.4% | — |
| Net Debt | -0 | -5 | 596 | 703 | — |
| Cash & Equivalents | 0 | 5 | 4 | 49 | — |
| Total Debt | N/A | N/A | 600 | 752 | — |
| Liquidity & working capital | |||||
| Current Ratio | 0.00x | 0.19x | 1.47x | N/A | — |
| Quick Ratio | 0.00x | 0.19x | 1.47x | N/A | — |
| Cash Ratio | 0.01x | 0.01x | 0.02x | N/A | — |
| Total Current Assets | 0 | 75 | 234 | 49 | — |
| Total Current Liabilities | 33 | 400 | 159 | N/A | — |
| Inventory | N/A | N/A | N/A | N/A | — |
| Trade Receivables | 283 | 69 | 105 | 38 | — |
| Trade Payables | 33 | 400 | 58 | N/A | — |
| Net Working Capital | -33 | -325 | 74 | 49 | — |
| Net Working Capital % of Revenue | -5.3% | -56.7% | 14.5% | 9.9% | — |
| Trade Working Capital | 250 | -330 | 47 | 38 | — |
| Trade Working Capital % of Revenue | 40.5% | -57.6% | 9.1% | 7.8% | — |
| Change in Trade Working Capital | N/A | N/A | N/A | N/A | — |
| Turnover & efficiency | |||||
| Inventory Turnover | N/A | N/A | N/A | N/A | — |
| Days Inventory Outstanding (DIO) | N/A | N/A | N/A | N/A | — |
| Receivables Turnover | 2.18x | 8.26x | 4.90x | 12.89x | — |
| Days Sales Outstanding (DSO) | 167.3 | 44.2 | 74.5 | 28.3 | — |
| Payables Turnover | 0.87x | N/A | 1.51x | N/A | — |
| Days Payable Outstanding (DPO) | 417.8 | N/A | 242.3 | N/A | — |
| Cash Conversion Cycle | -250.5 days | 44.2 days | -167.8 days | 28.3 days | — |
| Asset Turnover | 0.28x | 0.36x | 0.43x | 0.47x | — |
| Cash flow & dividends | |||||
| Operating Cash Flow | 856 | -21 | N/A | N/A | — |
| Free Cash Flow (OCF − Capex proxy) | 856 | -21 | N/A | N/A | — |
| Cash Conversion (OCF / EBITDA) | 4572.9% | -14.6% | N/A | N/A | — |
| Dividends Declared | N/A | N/A | N/A | N/A | — |
| Dividend Payout Ratio | N/A | N/A | N/A | N/A | — |
| Cost of Funds | — | — | — | — | 10.2% |
| Cost / Income Ratio | — | — | — | — | 294.5% |
| Net Fee Income / Operating Income | — | — | — | — | 5.9% |
| Return on Avg Assets (ROAA) | — | — | — | — | 10.1% |
| Return on Avg Equity (ROAE) | — | — | — | — | 25.0% |